DUBLIN--(BUSINESS WIRE)--The "Nitric Oxide Synthase Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Nitric oxide synthase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Nitric oxide synthase inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Nitric oxide synthase inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Nitric oxide synthase inhibitors.
Nitric oxide synthase inhibitors Emerging Drugs Chapters
This segment of the Nitric oxide synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nitric oxide synthase inhibitors Emerging Drugs
VAS203: Vasopharm BIOTECH
VAS203 is an analogue of the natural co-factor biopterin, which is involved in the generation of nitric oxide by the Nitric Oxide Synthase (NOS) family of enzymes. The mechanism of action of VAS203 is believed to confer selective down regulation of inducible NOS (iNOS) without significantly inhibiting the function of other NOS enzymes.
Vasopharm's ronopterin (VAS203) missed its primary endpoint in the Phase III NOSTRA III study in patients with traumatic brain injury, but further analyses point to a significant clinical benefit when the inducible NOS inhibitor is given within 12 hours of trauma.
Nitric oxide synthase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Nitric oxide synthase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Nitric oxide synthase inhibitors
There are approx. 5+ key companies which are developing the therapies for Nitric oxide synthase inhibitors. The companies which have their Nitric oxide synthase inhibitors drug candidates in the most advanced stage, i.e. phase III include Vasopharm BIOTECH.
Key Questions Answered
- How many companies are developing Nitric oxide synthase inhibitors drugs?
- How many Nitric oxide synthase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nitric oxide synthase inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nitric oxide synthase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nitric oxide synthase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Companies Mentioned
- EyePoint Pharmaceuticals
- Reata Pharmaceuticals
- vasopharm BIOTECH
- Yiviva
- NeurAxon
- Neurophyxia
- SaNOtize Research and Development
- MediciNova
Key Topics Covered:
Introduction
Executive Summary
Nitric oxide synthase inhibitors: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
VAS203: Vasopharm BIOTECH
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
2-iminobiotin: Neurophyxia
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Nitric oxide synthase inhibitors Key Companies
Nitric oxide synthase inhibitors Key Products
Nitric oxide synthase inhibitors- Unmet Needs
Nitric oxide synthase inhibitors- Market Drivers and Barriers
Nitric oxide synthase inhibitors- Future Perspectives and Conclusion
Nitric oxide synthase inhibitors Analyst Views
Nitric oxide synthase inhibitors Key Companies
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/qdg7hb
